[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1995026411A3 - Composition and methods for creating syngeneic recombinant virus-producing cells - Google Patents

Composition and methods for creating syngeneic recombinant virus-producing cells Download PDF

Info

Publication number
WO1995026411A3
WO1995026411A3 PCT/US1995/003729 US9503729W WO9526411A3 WO 1995026411 A3 WO1995026411 A3 WO 1995026411A3 US 9503729 W US9503729 W US 9503729W WO 9526411 A3 WO9526411 A3 WO 9526411A3
Authority
WO
WIPO (PCT)
Prior art keywords
replication
virus
defective
nucleic acid
cells
Prior art date
Application number
PCT/US1995/003729
Other languages
French (fr)
Other versions
WO1995026411A2 (en
Inventor
Robert I Garver Jr
David T Curiel
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Priority to AU21948/95A priority Critical patent/AU2194895A/en
Publication of WO1995026411A2 publication Critical patent/WO1995026411A2/en
Publication of WO1995026411A3 publication Critical patent/WO1995026411A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Replication-defective viruses and means for intracellular replication thereof are described which are useful for gene therapy. Human cells can be changed into recombinant replication-defective virus particle-producing cells by the simultaneous delivery to those cells of two different nucleic acids: the first being a replication-defective viral genome, the second being a nucleic acid that complements the viral sequences deleted from the first nucleic acid so as to result in the production of new infective virus. The first nucleic acid can be delivered by the replication-defective virus itself or, as a nucleic acid that is not part of the virus. In a preferred embodiment, the replication-defective virus includes elements to maintain the two nucleic acids in combination during transduction. Examples of preferred viral sources are adenoviruses, herpesvirus, retroviruses, and adeno-associated viruses. Nucleic acids useful for gene therapy include those that code for proteins used to identify cells infected with the recombinant virus, those that encode for proteins that function to kill cells containing the viral genome, or that encode for therapeutic proteins that will serve to treat a pathophysiologic condition within the body.
PCT/US1995/003729 1994-03-25 1995-03-24 Composition and methods for creating syngeneic recombinant virus-producing cells WO1995026411A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21948/95A AU2194895A (en) 1994-03-25 1995-03-24 Composition and methods for creating syngeneic recombinant virus-producing cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21821794A 1994-03-25 1994-03-25
US218,217 1994-03-25

Publications (2)

Publication Number Publication Date
WO1995026411A2 WO1995026411A2 (en) 1995-10-05
WO1995026411A3 true WO1995026411A3 (en) 1996-07-18

Family

ID=22814221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003729 WO1995026411A2 (en) 1994-03-25 1995-03-24 Composition and methods for creating syngeneic recombinant virus-producing cells

Country Status (2)

Country Link
AU (1) AU2194895A (en)
WO (1) WO1995026411A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3816518B2 (en) * 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド Complementary adenoviral vector systems and cell lines
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2741358B1 (en) * 1995-11-17 1998-01-02 Centre Nat Rech Scient PRODUCTION OF RETROVIRAL VECTORS VIA DNA VIRUS-BASED VIRAL VECTORS
FR2747046B1 (en) * 1996-04-05 1998-06-19 Univ Paris Curie NEW PLASMOVIRUS VACCINES
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
BR0116756A (en) 2000-12-28 2005-01-04 Wyeth Corp Recombinant protective protein for streptococcus pneumoniae and its use
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7648772B2 (en) * 2005-06-28 2010-01-19 International Paper Co. Moisture resistant container
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
JP2012508174A (en) 2008-11-05 2012-04-05 ワイス・エルエルシー Multi-component immunogenic composition for preventing β-hemolytic streptococci (BHS) disease
PL3246044T5 (en) 2010-08-23 2024-06-17 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2728282T3 (en) 2010-09-10 2019-10-23 Wyeth Llc Non-lipidated variants of ORF2086 antigens from Neisseria meningitidis
CN104428009A (en) 2012-02-07 2015-03-18 全球生物疗法美国有限公司 Compartmentalized method of nucleic acid delivery and compositions and uses thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
RU2665841C2 (en) 2012-03-09 2018-09-04 Пфайзер Инк. Neisseria meningitidis compositions and methods of use thereof
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
WO2015021443A1 (en) 2013-08-08 2015-02-12 Global Bio Therapeutics Usa, Inc. Clamp device for minimally invasive procedures and uses thereof
RU2662968C2 (en) 2013-09-08 2018-07-31 Пфайзер Инк. Immunogenic composition for neisseria meningitidis (options)
WO2015127094A1 (en) 2014-02-19 2015-08-27 University Of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
RU2723045C2 (en) 2015-02-19 2020-06-08 Пфайзер Инк. Compositions of neisseria meningitidis and methods for preparation thereof
PE20191107A1 (en) 2017-01-31 2019-08-26 Pfizer COMPOSITIONS OF NEISSERIA MENINGITIDIS AND RESPECTIVE METHODS
JP2024531827A (en) 2021-08-13 2024-08-29 トリオヴァンス ホールディング リミテッド ライアビリティ カンパニー Skin substitute compositions and methods of making and using same - Patents.com
WO2023225160A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007283A1 (en) * 1991-09-30 1993-04-15 Boehringer Ingelheim International Gmbh Composition for inserting nucleic acid complexes into higher eucaryotic cells
WO1993019092A1 (en) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007283A1 (en) * 1991-09-30 1993-04-15 Boehringer Ingelheim International Gmbh Composition for inserting nucleic acid complexes into higher eucaryotic cells
WO1993019092A1 (en) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANOS, O. AND MULLIGAN, R.C.: "Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges", PROC.NATL.ACAD.SCI.USA, vol. 85, 1988, pages 6460 - 6464, XP002002814 *
GOLDSMITH, K.T. ET AL.: "Trans Complementation of an E1A-Deleted Adenovirus with Codelivered E1A Sequences to Make Recombinant Adenoviral Producer Cells", HUMAN GENE THERAPY, vol. 5, November 1994 (1994-11-01), pages 1341 - 1348, XP002002815 *
WAGNER, E. ET AL.: "Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes", PROC.NATL.ACAD.SCI.USA, vol. 89, July 1992 (1992-07-01), pages 6099 - 6103, XP002002816 *

Also Published As

Publication number Publication date
AU2194895A (en) 1995-10-17
WO1995026411A2 (en) 1995-10-05

Similar Documents

Publication Publication Date Title
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
EP1005376A4 (en) Methods and compositions for use in gene therapy for treatment of hemophilia
EE05138B1 (en) Recombinant MVA Virus and Its Uses, Isolated Eukaryotic Cell, Method for Recombinant HIV Nef Protein, and Vaccine
ES2157109T3 (en) CYTOPATHIC VIRUSES FOR THE TREATMENT AND PROFILASIS OF NEOPLASIA.
MXPA02005525A (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus.
EP0319570A4 (en) Recombinant human cytomegalovirus containing foreign gene and use thereof
JP2004501650A5 (en)
EP0256677A3 (en) Pseudorabies virus recombinants and their use in the production of proteins
WO1997004099A3 (en) Papillomaviruses, agents for detecting them and for treating diseases caused by such viruses
AU7514087A (en) Vaccine containing the protein f of the aids virus
WO1998023752A3 (en) Papilloma viruses, agents for detecting the same and for treating diseases caused by such viruses
AU698242B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
FI964784A0 (en) Virus recombinants, preparation and use in gene therapy
Rusconi et al. Vectors for gene delivery
Rice Synthetic bovine parainfluenza virus.
MY119381A (en) Recombinant mva virus, and the use thereof
MY157873A (en) Recombinant mva virus, and the use thereof
TH63069A (en) Infectious mud

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA